Novo Nordisk executives overlooked warnings ahead of Wegovy’s launch, leading to supply issues, high costs, and challenges competing with Eli Lilly’s Zepbound.
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Where Today's News Shapes Tomorrow
